Physician profile
Debra A Schaffer
NPI 1124268651
$4,563.89
in general payments reported to CMS, 2019-2025
41 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $977 · 2023: $1,377 · 2024: $741 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.87 |
| Education | $120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.28 | 2022-2025 | |
| Eisai INC. | $438.84 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.19 | 2021-2024 | Opdivo, Reblozyl, Eliquis |
| Janssen Biotech, INC. | $302.93 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $292.58 | 2021-2023 | Lumakras |
| Incyte Corporation | $264.10 | 2021-2023 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $231.85 | 2022-2024 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $231.70 | 2022-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $204.39 | 2021-2025 | |
| Lilly USA, LLC | $175.42 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $167.39 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.39 | 2021-2024 | Fruzaqla, Ninlaro |
| Myriad Genetic Laboratories, INC. | $102.26 | 2023 | Precisetumor |
| Genentech USA, INC. | $101.86 | 2022-2023 | Alecensa, Tecentriq |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $96.68 | 2021-2023 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $91.63 | 2021-2023 | Enhertu, Lynparza |
| Seagen INC. | $81.69 | 2021-2023 | Padcev |
| Genzyme Corporation | $78.79 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $63.96 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Puma Biotechnology, INC. | $51.87 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $50.12 | 2021-2023 | Imbruvica |
| Taiho Oncology, INC. | $47.55 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $45.92 | 2021-2022 | |
| Daiichi Sankyo INC. | $43.58 | 2022-2024 | Injectafer |
| Pharmaessentia USA Corporation | $37.60 | 2023-2024 | Besremi |
| Deciphera Pharmaceuticals INC. | $37.18 | 2021-2025 | Romvimza, Qinlock |
| Regeneron Healthcare Solutions, INC. | $33.71 | 2022-2023 | Libtayo |
| Exelixis INC. | $32.52 | 2021-2023 | Cabometyx |
| Kite Pharma, INC. | $30.09 | 2022-2023 | |
| Eusa Pharma (US) LLC | $27.65 | 2021 | |
| Gilead Sciences, INC. | $27.34 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $24.09 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Nestle Healthcare Nutrition INC. | $18.72 | 2021 | |
| Adc Therapeutics America, INC. | $18.18 | 2025 | |
| Kyowa Kirin, INC. | $17.66 | 2024 | Poteligeo |
| Astellas Pharma US INC | $15.15 | 2021 | |
| Array Biopharma INC | $13.00 | 2021 | |
| Morphosys, US INC. | $12.94 | 2021 | |
| Beigene USA, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.